In a big victory for patients who depend on prescription drugs, a federal judge struck down a 2021 HHS rule that allowed health insurers to not count drug manufacturer copay assistance towards a patient's out-of-pocket costs.

Providing a benefits package that thoughtfully addresses employee's needs is an essential component of fostering a sense of inclusion that complements and supercharges DEI&B efforts.

All the manufacturers of the first 10 prescription drugs selected for Medicare price negotiations agreed to participate by the Oct. 1 deadline, however, the process could be complicated by lawsuits filed by all of these drugmakers.

Conditions such as cancer, cardiovascular issues and high blood pressure are expected to drive medical costs in 2024, according to Aon.